Caris Life Sciences (CAI) Assets Average (2025 - 2026)

Caris Life Sciences' (CAI) quarterly Assets Average came in at $1.1 billion in Q1 2026, up 8.43% quarter-over-quarter from $1.1 billion in Q4 2025.

Caris Life Sciences (CAI) Assets Average (2025 - 2026) Analysis & Trends

Caris Life Sciences' Assets Average history runs 2 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

On a quarterly basis, Assets Average changed N/A year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $734.7 million, changed N/A from the prior year.
Assets Average improved to $1.1 billion in Q1 2026 per CAI's latest filing, from $1.1 billion in the prior quarter.
Across five years, Assets Average topped out at $1.1 billion in Q1 2026 and bottomed at $969.8 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets Avg. (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	303.40 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	65.01 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	8.37 Bn
4	NuCana	279.75 Bn	279.75 Bn	-	41.64 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	26.06 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	40.71 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	795.91 Mn
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	2.30 Bn
10	Caris Life Sciences	4.42 Bn	3.60 Bn	214.23 Mn	1.14 Bn

Download Data